These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 21212980)

  • 1. Antileishmanial efficacy of fluconazole and miltefosine in combination with an immunomodulator--picroliv.
    Shakya N; Sane SA; Gupta S
    Parasitol Res; 2011 Apr; 108(4):793-800. PubMed ID: 21212980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
    Shakya N; Sane SA; Vishwakarma P; Bajpai P; Gupta S
    Acta Trop; 2011 Aug; 119(2-3):188-93. PubMed ID: 21679679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis.
    Sane SA; Shakya N; Gupta S
    Exp Parasitol; 2011 Feb; 127(2):376-81. PubMed ID: 20846525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
    Sane SA; Shakya N; Haq W; Gupta S
    J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of picroliv in combination with miltefosine, an orally effective antileishmanial drug against experimental visceral leishmaniasis.
    Gupta S; Ramesh SC; Srivastava VM
    Acta Trop; 2005 Apr; 94(1):41-7. PubMed ID: 15895483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Augmentation of antileishmanial efficacy of miltefosine in combination with tuftsin against experimental visceral leishmaniasis.
    Shakya N; Sane SA; Haq W; Gupta S
    Parasitol Res; 2012 Aug; 111(2):563-70. PubMed ID: 22392136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effect of Picroliv from Picrorhiza kurroa against Leishmania donovani infections in Mesocricetus auratus.
    Mittal N; Gupta N; Saksena S; Goyal N; Roy U; Rastogi AK
    Life Sci; 1998; 63(20):1823-34. PubMed ID: 9820126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement in therapeutic efficacy of miltefosine in combination with synthetic bacterial lipopeptide, Pam3Cys against experimental Visceral Leishmaniasis.
    Shakya N; Sane SA; Vishwakarma P; Gupta S
    Exp Parasitol; 2012 Jul; 131(3):377-82. PubMed ID: 22626518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
    Tiwari B; Pahuja R; Kumar P; Rath SK; Gupta KC; Goyal N
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.
    Gupta R; Kushawaha PK; Samant M; Jaiswal AK; Baharia RK; Dube A
    J Antimicrob Chemother; 2012 Feb; 67(2):440-3. PubMed ID: 22121191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Withania somnifera chemotype NMITLI 101R significantly increases the efficacy of antileishmanial drugs by generating strong IFN-γ and IL-12 mediated immune responses in Leishmania donovani infected hamsters.
    Tripathi CD; Kushawaha PK; Sangwan RS; Mandal C; Misra-Bhattacharya S; Dube A
    Phytomedicine; 2017 Jan; 24():87-95. PubMed ID: 28160866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of liposomal CpG oligodeoxynucleotide 2006 and miltefosine induces strong cell-mediated immunity during experimental visceral leishmaniasis.
    Shivahare R; Vishwakarma P; Parmar N; Yadav PK; Haq W; Srivastava M; Gupta S; Kar S
    PLoS One; 2014; 9(4):e94596. PubMed ID: 24732039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum.
    Hendrickx S; Van den Kerkhof M; Mabille D; Cos P; Delputte P; Maes L; Caljon G
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005620. PubMed ID: 28505185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The preclinical discovery and development of oral miltefosine for the treatment of visceral leishmaniasis: a case history.
    Reimão JQ; Pita Pedro DP; Coelho AC
    Expert Opin Drug Discov; 2020 Jun; 15(6):647-658. PubMed ID: 32202449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet-activating factor receptor contributes to antileishmanial function of miltefosine.
    Gangalum PR; de Castro W; Vieira LQ; Dey R; Rivas L; Singh S; Majumdar S; Saha B
    J Immunol; 2015 Jun; 194(12):5961-7. PubMed ID: 25980013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and Evaluation of Methyl 4-(7-Hydroxy-4,4,8-Trimethyl-3-Oxabicyclo[3.3.1]Nonan-2-yl)Benzoate as an Antileishmanial Agent and Its Synergistic Effect with Miltefosine.
    Bhalla P; Sultana S; Chiranjivi AK; Saikia AK; Dubey VK
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leptin augments protective immune responses in murine macrophages and enhances potential of miltefosine against experimental visceral leishmaniasis.
    Shivahare R; Ali W; Vishwakarma P; Natu SM; Puri SK; Gupta S
    Acta Trop; 2015 Oct; 150():35-41. PubMed ID: 26119043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
    Gangneux JP; Marty P
    Sante; 2001; 11(4):257-8. PubMed ID: 11861203
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
    Seifert K; Croft SL
    Antimicrob Agents Chemother; 2006 Jan; 50(1):73-9. PubMed ID: 16377670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.